RxPBM ClinicalRx RxBenefits RxNews RxInfo A BuiltForAI Property

You're paying more
than you should.

Every pharmacy benefit was engineered by someone who profits from your confusion. PBM contracts, rebate clawbacks, formulary manipulation. We expose what they hide.

Ask anything about your pharmacy benefits
Ozempic pricing Spread pricing Copay increase GLP-1 alternatives Biosimilar savings
RxBenefits.ai Intelligence

The average American overpays for prescriptions by $1,200 a year.

When you search here, something different happens. We don't give you a chatbot answer scraped from the internet. We pull live pricing data from RxPBM.ai — what your plan actually pays versus what the pharmacy receives versus what the manufacturer charges.

Then we check ClinicalRx.ai for pipeline alternatives. Biosimilars in development. Generics pending approval. Therapeutic alternatives in late-stage trials that could cut your cost by 40%.

Then we pull context from RxInfo.ai and track regulatory shifts on RxNews.ai. One question, five systems, a complete answer.

No single website can give you the whole picture. That's why we built five.

Patient
For patients & consumers

Find out why you pay what you pay.

Your pharmacy benefit isn't designed for you. It's designed for intermediaries who profit from complexity. Ask a question and get real data — pricing spreads, pipeline alternatives, formulary education — from five specialized systems working together.

Employer
For employers & brokers

See what your workforce can't tell you.

When employees search for drug alternatives, compare prices, or ask why their copay changed — that's a signal. Aggregated across thousands, it predicts dissatisfaction and attrition before any survey catches it.

From the network

What's happening in pharmacy benefits right now

RxNews.ai · Regulatory

Commissioner's National Priority Voucher (CNPV) Pilot Program

FDA launches program offering unprecedented opportunity to reduce drug and biologic review times from 10-12 months. Priority review vouchers could reshape the competitive landscape for rare disease treatments.
Feb 9, 2026
RxNews.ai · Industry

OHSU Board Votes to Negotiate with NIH and Transform Its Primate Research Center

Major shift in research funding as OHSU moves to renegotiate primate center operations with NIH, signaling broader changes in how pharmaceutical research gets funded and governed.
Feb 9, 2026
RxNews.ai · Industry

FDA Warned Hims & Hers Compounder After Finding Bugs and Quality Failures

Compounding pharmacy supplying telehealth giant flagged for contamination and quality control violations. Raises questions about the safety of compounded GLP-1 alternatives flooding the market.
Feb 9, 2026
RxNews.ai · Regulatory

Safety Labeling Update for Capecitabine and Fluorouracil (5-FU) on DPD Deficiency Risks

FDA updates safety labeling for two widely-used chemotherapy drugs to address risks associated with DPD deficiency. Pharmacogenomic testing implications for oncology benefits.
Feb 9, 2026
RxNews.ai · Clinical

FDA Rejects Regenxbio's Hunter Syndrome Gene Therapy

Complete response letter issued for rare-disease gene therapy. Setback highlights ongoing challenges in the gene therapy approval pipeline and cost implications for specialty pharmacy benefits.
Feb 8, 2026
RxNews.ai · Policy

With Scant Data, RFK Jr. Credits Trump for Higher European Drug Prices

HHS Secretary's claims about international drug pricing draw scrutiny. Analysis of how "most favored nation" pricing proposals could reshape pharmacy benefit structures and employer costs.
Feb 8, 2026
See all stories on RxNews.ai →
Understand the system

The guides your PBM hopes you never read.

What Is Spread Pricing and Why Does It Cost You Money?

RxInfo.ai

How Formulary Tier Decisions Are Really Made

RxInfo.ai

The Rebate Trap: Why Your "Preferred" Drug Costs More

RxInfo.ai

How to Read Your PBM Contract (And What They're Hiding)

RxPBM.ai

Biosimilars Explained: When Cheaper Alternatives Are Coming

ClinicalRx.ai

Step Therapy and Prior Auth: Your Rights When Treatment Is Denied

RxPBM.ai
FORMULARY TIERS REBATE CLAWBACKS SPREAD PRICING PRIOR AUTH STEP THERAPY COPAY ACCUMULATORS MAIL ORDER SPECIALTY PHARMACY DIR FEES NETWORK RESTRICTIONS AWP BENCHMARKS PASS-THROUGH EXCLUSION LISTS

You're drowning in pharmacy benefit jargon, but still can't get a straight answer.

Ask a question. We'll cut through all of it and tell you what actually matters — with data, not opinions.